| Eplerenone--a novel selective aldosterone blocker. | |
| | |
MedLine Citation:
|
PMID: 12243608 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of eplerenone, a new selective aldosterone blocker. DATA SOURCES: Primary literature and review articles were obtained via MEDLINE search (1966-April 2002). Additional studies and abstracts were identified from the bibliographies of reviewed literature. STUDY SELECTION AND DATA EXTRACTION: Studies and review articles related to eplerenone, aldosterone, aldosterone antagonist, and spironolactone were reviewed. Data pertinent to this article were included. DATA SYNTHESIS: Eplerenone is a selective aldosterone blocker. Recent data have demonstrated the deleterious effects of aldosterone in several chronic disease states including hypertension and heart failure. Animal studies using eplerenone have shown a positive role for aldosterone antagonism in the treatment of hypertension, heart failure, myocardial infarction, renal disease, and atherosclerosis. In humans, eplerenone appears to be effective for the treatment of hypertension. An ongoing study will examine the effect of eplerenone for heart failure. To date, the incidence of adverse effects with eplerenone has been slightly lower than with spironolactone. CONCLUSIONS: Eplerenone appears to be a promising drug in a new class of agents called selective aldosterone blockers. The drug may be approved for treatment of hypertension in 2002. Additional studies are ongoing that may provide information on other clinical uses for this medication. |
| | |
Authors:
|
Alan J Zillich; Barry L Carter |
Related Documents
:
|
22830618 - Drug fever: a descriptive cohort study from the french national pharmacovigilance datab... 22435438 - Comparative evaluation of griseofulvin, terbinafine and fluconazole in the treatment of... 22367108 - In vitro release profile of anti-ulcer drug rabeprazole from biocompatible psyllium-pva... 22820748 - Inhibition of candida albicans by fluvastatin is dependent on ph. 22830618 - Drug fever: a descriptive cohort study from the french national pharmacovigilance datab... 22305778 - Chlorhexidine delivery system from titanium/polybenzyl acrylate coating: evaluation of ... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: The Annals of pharmacotherapy Volume: 36 ISSN: 1060-0280 ISO Abbreviation: Ann Pharmacother Publication Date: 2002 Oct |
Date Detail:
|
Created Date: 2002-09-23 Completed Date: 2003-04-25 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9203131 Medline TA: Ann Pharmacother Country: United States |
Other Details:
|
Languages: eng Pagination: 1567-76 Citation Subset: IM |
Affiliation:
|
Division of Clinical and Administrative Pharmacy and Department of Family Medicine, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA. alan.zillich@uiowa.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone Antagonists
/
adverse effects,
pharmacokinetics,
pharmacology*,
therapeutic use Animals Clinical Trials as Topic Heart Failure / drug therapy Humans Hypertension / drug therapy Spironolactone / adverse effects, analogs & derivatives*, pharmacokinetics, pharmacology*, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/eplerenone; 52-01-7/Spironolactone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Nefopam abuse.
Next Document: Antidepressant-induced sexual dysfunction.